Beauty Health Analyst Ratings
Beauty Health Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 08/10/2023 | 131.42% | DA Davidson | $35 → $16.5 | Maintains | Buy |
| 08/08/2023 | 222.58% | Benchmark | → $23 | Reiterates | Buy → Buy |
| 06/21/2023 | 40.25% | Stifel | $17 → $10 | Downgrades | Buy → Hold |
| 05/26/2023 | 68.3% | JP Morgan | $13 → $12 | Maintains | Neutral |
| 05/18/2023 | 222.58% | Benchmark | → $23 | Reiterates | Buy → Buy |
| 05/11/2023 | 390.88% | DA Davidson | → $35 | Reiterates | → Buy |
| 03/28/2023 | 152.45% | Canaccord Genuity | → $18 | Reiterates | → Buy |
| 03/20/2023 | — | Exane BNP Paribas | Upgrades | Underperform → Neutral | |
| 03/14/2023 | 222.58% | Benchmark | → $23 | Reiterates | → Buy |
| 03/01/2023 | 390.88% | DA Davidson | $32 → $35 | Maintains | Buy |
| 02/28/2023 | 222.58% | Benchmark | → $23 | Reiterates | → Buy |
| 02/16/2023 | 110.38% | Cowen & Co. | $20 → $15 | Maintains | Outperform |
| 11/23/2022 | 166.48% | Goldman Sachs | $22 → $19 | Maintains | Buy |
| 11/09/2022 | 54.28% | JP Morgan | $22 → $11 | Downgrades | Overweight → Neutral |
| 11/09/2022 | 348.81% | DA Davidson | $31 → $32 | Maintains | Buy |
| 09/28/2022 | 334.78% | DA Davidson | $30 → $31 | Maintains | Buy |
| 09/16/2022 | 222.58% | Piper Sandler | $20 → $23 | Maintains | Overweight |
| 09/16/2022 | 320.76% | DA Davidson | $25 → $30 | Maintains | Buy |
| 08/16/2022 | 208.56% | Goldman Sachs | $25 → $22 | Maintains | Buy |
| 08/10/2022 | 180.5% | Piper Sandler | $22 → $20 | Maintains | Overweight |
| 08/10/2022 | 250.63% | DA Davidson | $24 → $25 | Maintains | Buy |
| 07/08/2022 | 208.56% | Piper Sandler | $24 → $22 | Maintains | Overweight |
| 06/30/2022 | 180.5% | Canaccord Genuity | $22 → $20 | Maintains | Buy |
| 05/12/2022 | 236.61% | DA Davidson | $35 → $24 | Maintains | Buy |
| 05/11/2022 | 250.63% | Goldman Sachs | $29 → $25 | Maintains | Buy |
| 05/11/2022 | 236.61% | Piper Sandler | $26 → $24 | Maintains | Overweight |
| 04/28/2022 | 264.66% | Piper Sandler | $31 → $26 | Maintains | Overweight |
| 03/14/2022 | 222.58% | Benchmark | $18 → $23 | Maintains | Buy |
| 03/11/2022 | 236.61% | JP Morgan | → $24 | Initiates Coverage On | → Overweight |
| 02/23/2022 | 390.88% | DA Davidson | $32 → $35 | Maintains | Buy |
| 01/07/2022 | — | William Blair | Initiates Coverage On | → Outperform | |
| 12/23/2021 | — | Raymond James | Initiates Coverage On | → Market Perform | |
| 11/10/2021 | 348.81% | DA Davidson | $26 → $32 | Maintains | Buy |
| 10/08/2021 | 362.83% | Stifel | → $33 | Initiates Coverage On | → Buy |
| 10/04/2021 | 348.81% | Cowen & Co. | → $32 | Initiates Coverage On | → Outperform |
| 08/11/2021 | 264.66% | DA Davidson | $17.5 → $26 | Maintains | Buy |
| 07/19/2021 | 208.56% | Jefferies | → $22 | Initiates Coverage On | → Buy |
| 07/01/2021 | 334.78% | Goldman Sachs | → $31 | Initiates Coverage On | → Buy |
| 06/24/2021 | 236.61% | Piper Sandler | → $24 | Initiates Coverage On | → Overweight |
| 06/15/2021 | 194.53% | Canaccord Genuity | → $21 | Initiates Coverage On | → Buy |
| 06/01/2021 | 145.44% | DA Davidson | $16 → $17.5 | Maintains | Buy |
| 日期 | 上行/下行 | 分析公司 | 目標價格變動 | 評級變動 | 之前/當前的評級 |
|---|---|---|---|---|---|
| 08/10/2023 | 131.42% | DA Davidson | 35 美元 → 16.5 美元 | 維護 | 購買 |
| 08/08/2023 | 222.58% | 基準 | → 23 美元 | 重申 | 購買 → 購買 |
| 06/21/2023 | 40.25% | Stifel | 17 美元 → 10 美元 | 降級 | 買入 → 持有 |
| 05/26/2023 | 68.3% | 摩根大通 | 13 美元 → 12 美元 | 維護 | 中立 |
| 05/18/2023 | 222.58% | 基準 | → 23 美元 | 重申 | 購買 → 購買 |
| 05/11/2023 | 390.88% | DA Davidson | → 35 美元 | 重申 | → 購買 |
| 03/28/2023 | 152.45% | Canaccord Genu | → 18 美元 | 重申 | → 購買 |
| 03/20/2023 | — | Exane BNP Paribas | 升級 | 表現不佳 → 中性 | |
| 03/14/2023 | 222.58% | 基準 | → 23 美元 | 重申 | → 購買 |
| 03/01/2023 | 390.88% | DA Davidson | 32 美元 → 35 美元 | 維護 | 購買 |
| 02/28/2023 | 222.58% | 基準 | → 23 美元 | 重申 | → 購買 |
| 02/16/2023 | 110.38% | Cowen & Co. | 20 美元 → 15 美元 | 維護 | 跑贏大盤 |
| 2022 年 11 月 23 日 | 166.48% | 高盛 | 22 美元 → 19 美元 | 維護 | 購買 |
| 11/09/2022 | 54.28% | 摩根大通 | 22 美元 → 11 美元 | 降級 | 超重 → 中性 |
| 11/09/2022 | 348.81% | DA Davidson | 31 美元 → 32 美元 | 維護 | 購買 |
| 2022 年 9 月 28 日 | 334.78% | DA Davidson | 30 美元 → 31 美元 | 維護 | 購買 |
| 2022 年 9 月 16 日 | 222.58% | 派珀·桑德勒 | 20 美元 → 23 美元 | 維護 | 超重 |
| 2022 年 9 月 16 日 | 320.76% | DA Davidson | 25 美元 → 30 美元 | 維護 | 購買 |
| 08/16/2022 | 208.56% | 高盛 | 25 美元 → 22 美元 | 維護 | 購買 |
| 08/10/2022 | 180.5% | 派珀·桑德勒 | 22 美元 → 20 美元 | 維護 | 超重 |
| 08/10/2022 | 250.63% | DA Davidson | 24 美元 → 25 美元 | 維護 | 購買 |
| 07/08/2022 | 208.56% | 派珀·桑德勒 | 24 美元 → 22 美元 | 維護 | 超重 |
| 06/30/2022 | 180.5% | Canaccord Genu | 22 美元 → 20 美元 | 維護 | 購買 |
| 2022 年 12 月 5 日 | 236.61% | DA Davidson | 35 美元 → 24 美元 | 維護 | 購買 |
| 05/11/2022 | 250.63% | 高盛 | 29 美元 → 25 美元 | 維護 | 購買 |
| 05/11/2022 | 236.61% | 派珀·桑德勒 | 26 美元 → 24 美元 | 維護 | 超重 |
| 04/28/2022 | 264.66% | 派珀·桑德勒 | 31 美元 → 26 美元 | 維護 | 超重 |
| 03/14/2022 | 222.58% | 基準 | 18 美元 → 23 美元 | 維護 | 購買 |
| 03/11/2022 | 236.61% | 摩根大通 | → 24 美元 | 啓動覆蓋開啓 | → 超重 |
| 2022 年 2 月 23 日 | 390.88% | DA Davidson | 32 美元 → 35 美元 | 維護 | 購買 |
| 2022 年 7 月 1 日 | — | 威廉布萊爾 | 啓動覆蓋開啓 | → 跑贏大盤 | |
| 12/23/2021 | — | 雷蒙德·詹姆 | 啓動覆蓋開啓 | → 市場表現 | |
| 11/10/2021 | 348.81% | DA Davidson | 26 美元 → 32 美元 | 維護 | 購買 |
| 2021 年 8 月 10 日 | 362.83% | Stifel | → 33 美元 | 啓動覆蓋開啓 | → 購買 |
| 2021 年 4 月 10 日 | 348.81% | Cowen & Co. | → 32 美元 | 啓動覆蓋開啓 | → 跑贏大盤 |
| 08/11/2021 | 264.66% | DA Davidson | 17.5 美元 → 26 美元 | 維護 | 購買 |
| 07/19/2021 | 208.56% | 傑富瑞 | → 22 美元 | 啓動覆蓋開啓 | → 購買 |
| 07/01/2021 | 334.78% | 高盛 | → 31 美元 | 啓動覆蓋開啓 | → 購買 |
| 2021 年 6 月 24 日 | 236.61% | 派珀·桑德勒 | → 24 美元 | 啓動覆蓋開啓 | → 超重 |
| 06/15/2021 | 194.53% | Canaccord Genu | → 21 美元 | 啓動覆蓋開啓 | → 購買 |
| 06/01/2021 | 145.44% | DA Davidson | 16 美元 → 17.5 美元 | 維護 | 購買 |
What is the target price for Beauty Health (SKIN)?
Beauty Health（SKIN）的目標價格是多少？
The latest price target for Beauty Health (NASDAQ: SKIN) was reported by DA Davidson on August 10, 2023. The analyst firm set a price target for $16.50 expecting SKIN to rise to within 12 months (a possible 131.42% upside). 19 analyst firms have reported ratings in the last year.
DA Davidson於2023年8月10日公佈了Beauty Health（納斯達克股票代碼：SKIN）的最新目標股價。這家分析公司將目標股價定爲16.50美元，預計SKIN將在12個月內升至16.50美元（可能上漲131.42％）。去年有19家分析公司公佈了評級。
What is the most recent analyst rating for Beauty Health (SKIN)?
分析師對美容健康（SKIN）的最新評級是多少？
The latest analyst rating for Beauty Health (NASDAQ: SKIN) was provided by DA Davidson, and Beauty Health maintained their buy rating.
Beauty Health（納斯達克股票代碼：SKIN）的最新分析師評級由DA Davidson提供，Beauty Health維持買入評級。
When is the next analyst rating going to be posted or updated for Beauty Health (SKIN)?
Beauty Health（SKIN）的下一個分析師評級何時公佈或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Beauty Health, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Beauty Health was filed on August 10, 2023 so you should expect the next rating to be made available sometime around August 10, 2024.
分析師在進行了廣泛的研究（包括瀏覽公開財務報表、與Beauty Health的高管和客戶交談以及聽取業績電話會議）後得出了股票評級。大多數分析師每三個月進行一次評級，因此每家公司每年應該獲得4個評級。Beauty Health 的最新評級是在2023年8月10日提交的，因此您應該預計下一個評級將在2024年8月10日左右公佈。
Is the Analyst Rating Beauty Health (SKIN) correct?
分析師對美容健康 (SKIN) 的評級是否正確？
While ratings are subjective and will change, the latest Beauty Health (SKIN) rating was a maintained with a price target of $35.00 to $16.50. The current price Beauty Health (SKIN) is trading at is $7.13, which is out of the analyst's predicted range.
雖然評級是主觀的，會發生變化，但最新的Beauty Health（SKIN）評級維持不變，目標股價爲35.00美元至16.50美元。Beauty Health（SKIN）目前的交易價格爲7.13美元，超出了分析師的預測區間。